Lipid metabolism disruptions drive chronic inflammation, causing colorectal cancer progression.
Recent research highlights the significant role of lipid metabolism in the progression of colorectal cancer, providing new insights into how chronic inflammation may contribute to tumor growth and identifying potential therapeutic avenues. Lipids, beyond their traditional functions in energy storage and structural integrity, are active participants in cell signaling pathways. Their role in inflammation is particularly important, as imbalances in lipid mediators can cause chronic inflammatory states, a known driver of colorectal cancer progression.
In healthy tissue, inflammation typically resolves through a regulated process known as lipid mediator class switching. This process involves a transition from pro-inflammatory to inflammation-resolving lipid molecules, such as lipoxins and resolvins. However, in colorectal cancer, this is disrupted. Pro-inflammatory mediators, including leukotrienes created from arachidonic acid, are overproduced, while inflammation-resolving mediators are nearly nonexistent. This imbalance creates a microenvironment conducive to tumor growth and immune evasion.
A recent study published in Gut integrated lipidomics with advanced molecular and spatial transcriptomics to explore this phenomenon. Researchers analyzed paired tumor and normal tissue samples from colorectal cancer patients, focusing on the specific lipid profiles and the expression of genes involved in lipid metabolism. Using advanced techniques like liquid chromatography-tandem mass spectrometry, they quantified lipid mediators and mapped the spatial expression of related enzymes within tumor tissues.
The findings revealed a significant amount of pro-inflammatory lipid mediators in cancerous tissues. Arachidonate 5-lipoxygenase (ALOX5), an enzyme responsible for producing leukotrienes, was highly expressed in tumor-associated macrophages (TAMs). These immune cells, often recruited to tumor sites, were identified as key contributors to the inflammatory lipid profile. The team also observed a reduction in the expression of enzymes involved in the synthesis of resolving mediators, such as arachidonate 15-lipoxygenase (ALOX15).
Dietary factors also play a role in determining lipid metabolism. The study highlighted the impact of Western diets, which are rich in omega-6 fatty acids. These fats are precursors to pro-inflammatory lipids and have been linked to the elevated production of molecules like leukotrienes. At the same time, omega-3 fatty acids, found in foods such as fish and flaxseed, are precursors to resolving mediators. The imbalance between these dietary fats may contribute to the metabolic disruptions observed in colorectal cancer.
Spatial transcriptomics provided additional insights by showing the co-localization of pro-inflammatory enzymes and lipid mediators with immune and stromal cells in the tumor microenvironment. This suggests that the inflammatory state is not merely a byproduct of tumor activity but an integral component of tumor progression.
Therapeutic strategies targeting these pathways hold promise. One potential approach involves the use of specialized pro-resolving mediators (SPMs) such as resolvins and protectins. These molecules, derived from omega-3 fatty acids, can help restore the balance between pro-inflammatory and resolving mediators. By promoting the resolution of inflammation, SPMs could reduce the chronic inflammatory state that supports tumor growth.
Another avenue is the modulation of lipid-metabolizing enzymes. Inhibiting ALOX5 or enhancing the activity of ALOX15 could shift the lipid mediator profile toward resolution, potentially disrupting the tumor-promoting environment.
Ultimately, the integration of lipidomics with advanced molecular techniques provides a powerful tool for understanding the role of lipid metabolism in colorectal cancer. By identifying the specific mechanisms that sustain chronic inflammation, researchers can develop targeted interventions to disrupt these pathways, offering a potential avenue for improving colorectal cancer outcomes.
Sources:
Lipid imbalances hold the key to chronic inflammation in colon cancer
Join the conversation!